Search results
MEI Pharma, Kyowa Kirin Cull Development Of Blood Cancer Drug Outside Japan, Look For Strategic...
Benzinga via Yahoo Finance· 1 year agoMEI Pharma Inc (NASDAQ: MEIP) and Kyowa Kirin Co Ltd are discontinuing global development of...
Orchard Therapeutics PLC (ORTX) Reports Q3 2023 Earnings and Announces Acquisition by Kyowa Kirin
GuruFocus.com via Yahoo Finance· 6 months agoORTX reports $5.6 million in Q3 Libmeldy net revenue, with a year-to-date total of $12.7 million....
Kyowa Kirin's gene therapy most expensive US drug with $4.3 million price tag
Reuters via Yahoo Finance· 2 months agoThe therapy was approved on Monday, in a first for children with a rare disorder called...
BridgeBio sells partial rights to dwarfism drug for $100M
BioPharma Dive via Yahoo Finance· 4 months agoDive Brief: BridgeBio Pharma is selling partial rights to an experimental drug for a common form of...
Orchard (ORTX) Up 97% on $478M Acquisition Deal With Kyowa Kirin
Zacks via Yahoo Finance· 8 months agoOrchard (ORTX) is set to be acquired by Kyowa Kirin for a consideration of $17 per American...
Highly Rated Biotech Orchard Therapeutics Scores A Takeover, Shares Nearly Double
Investor's Business Daily· 8 months agoOrchard Therapeutics scored a buyout deal worth up to $478 million from Japan's Kyowa Kirin on...
Ultragenyx Sells One-Third Of Future North American Crysvita Royalties For $500M
Benzinga via Yahoo Finance· 2 years agoUltragenyx Pharmaceutical Inc (NASDAQ: RARE) announced the sale of 30% of its royalty interest from...
Orchard follows buyout with FDA approval of rare disease gene therapy
BioPharma Dive via Yahoo Finance· 2 months agoThe U.S. clearance of Lenmeldy, for a rare and inherited metabolic disease, triggers an additional...
Sanford plans for 100 new jobs as latest Japanese company picks North Carolina
Raleigh News and Observer via Yahoo News· 3 months agoA Japanese biotech manufacturer promises to build its first North American manufacturing facility in...
Analyst Upgrades This Stock And Doubles Price Target On Encouraging Ibsrela Story
Benzinga via Yahoo Finance· 1 year agoAfter the market close Thursday, Ardelyx Inc (NASDAQ: ARDX) reported Q4 FY22 Ibsrela sales of $8.7...